vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 45.45 percent increase over losses of $(0.11) per share from the same period last year. The company reported $9.00 thousand in sales this quarter. This is the same as the same period last year.
Related Posts
EXCLUSIVE: Why This Cannabis Finance Exec Fears The SAFE Banking Act May Not Survive In Present Form
Leonard Tannenbaum, founder, chairman and CEO of AFC Gamma Inc (NASDAQ: AFCG), does not hold much hope the SAFE Banking Act will pass into law this year
AEye Shares Falls After Q4 Results, FY22 Outlook Trails Consensus
AEye Inc (NASDAQ:LIDR) reported fourth-quarter revenue of $1.8 million, compared to $279 thousand in 4Q20. It reported a gross loss…